Aging is the primary risk factor for neurodegenerative diseases of aging, including Alzheimer’s disease (AD - the most common cause of dementia in the developed world). Certain genetic factors increase risk, while environmental factors (lifestyle) decrease risk. Strategies to delay or prevent dementia and AD will be discussed (i.e., how to avoid the dementia clinic). Recognition of cognitive decline with aging, and diagnostic criteria for the more common dementias will be reviewed. Current treatment options for AD will be reviewed, as well as innovative strategies now in the pipeline (phase 2 and 3 clinical trials). Novel biomarkers (amyloid PET, spinal fluid proteins, genetic testing) enable identification of high-risk cognitively normal individuals for prevention trials.
Recognize the genetic and environmental risk factors for cognitive decline, dementia, and Alzheimer’s disease (AD).
Define the diagnostic criteria for prodromal AD, mild cognitive impairment (MCI), and AD, including novel biomarkers.
Review current treatment options for AD - and novel treatments in the research and development pipeline.